Clinical Evaluation of the Effects of a New Long-Acting Superactive Luteinizing Hormone-Releasing Hormone (LH-RH) Analog, d-Ser(TBU)6-des-Gly-10-Ethylamide-LH-RH, in Women with Secondary Amenorrhea

Katzorke, Thomas; Propping, D.; Ohe, M. von der; Tauber, P. F.

doi:10.1016/s0015-0282(16)44474-2

“…Therapeutic response to L H R H agonists in primary amenorrhoea has been disappointing. Similarly, various regimens of administration of agonists in secondary amenorrhoea have also not been encouraging (Jaramillo-Jaramillo et Cortes-Prieto et al 1979;Katzorke et al 1980). A novel approach to the management of infertility associated with abnormal hormonal profiles has been undertaken by Fleming et al (1982). 1981).…”

Section: Ovulation Inductionmentioning

confidence: 99%

Clinical aspects of LHRH analogues in gynaecology: a review

McLachlan

¹

,

Healy

²

,

Burger

³

1986

BJOG

View full text Add to dashboard Cite

LHRH agonists are synthetic peptide analogues of hypothalamic luteinizing hormone releasing hormone (LHRH) with superior potency and longer duration of gonadotrophin release. Paradoxically, repeated administration causes pituitary desensitization with diminished gonadotrophin and oestradiol secretion. A state of hypogonadotrophic hypogonadism is reversibly induced; plasma oestrogen can be reduced to castrate levels. LHRH agonists reliably induce anovulation but are unlikely to replace existing contraceptive methods in most normal women. By contrast these agents offer, for the first time, the prospect of inducing a reversible pseudomenopause essentially free of side-effects. LHRH analogues promise to have a profound impact upon the management of a diverse range of oestrogen-dependent gynaecological diseases both benign and malignant. In particular, they may shortly become the gynaecological treatment of choice in endometriosis, as well as becoming part of the management of common gynaecological disorders such as dysfunctional uterine bleeding and uterine fibroids.

show abstract

“…These ana¬ logues have found some clinical application in the treatment of hypothalamic amenorrhoea and in¬ duction of ovulation (Nillius et al 1975;Nillius & Wide 1977;Katzorke et al 1980;Bartinos et 1979; Nillius & Wide 1977Nillius et al 1978Schallyetal. 1980).…”

Section: Discussionmentioning

confidence: 99%

The effect of D-Trp6-LRH upon secretion of gonadotrophin – a possible therapeutic application in anorexia nervosa

Zgliczyński

¹

,

Baranowska

²

,

Jeske

³

et al. 1984

Acta Endocrinologica

10

0

View full text Add to dashboard Cite

The aim of this study was to evaluate the effect of the agonistic LRH analogue (D-Trp6-LRH) on LH, FSH and prolactin secretion, and its possible efficacy in female patients with anorexia nervosa. The study included 18 female patients with anorexia nervosa and 7 healthy women in the same age group. The patients with anorexia nervosa were divided into two groups of 9 women each. The first group consisted of patients in the weight loss phase of the disorder and the second of 9 women who had achieved normal body weight. Additionally, in 6 women with anorexia nervosa serum LH concentration was determined in response to native LRH before and 14 days after the treatment with D-Trp6\x=req-\ LRH.Serum LH, FSH, prolactin concentrations were determined before and 5, 10, 24 and 48 h after administration of D-Trp6-LRH in a dose of 5 \g=m\g. The serum LH response to D-Trp6-LRH in the second group did not differ from that of the control group. However, in women with anorexia nervosa in the weight loss phase, LH release in response to administration of the analogue was significantly lower. FSH release after LRH analogue administration in both groups of patients with anorexia nervosa did not differ from that in the control group. The increased LH secretion in response to native LRH after treatment indicates that D-Trp6-LRH in low doses did not inhibit pituitary responsiveness. A dose of 5 \ g=m\ g of D-Trp6-LRH was administered in a therapeutic regimen every 48 h from 1 to 3 months to 7 of 9 patients with anorexia nervosa who exhibited amenorrhoea in spite of normalization of body weight. All the patients treated with the analogue resumed menstruation. The results of this study suggest that D-Trp6-LRH may be of value in the treatment of amenorrhoea in women with anorexia nervosa.

show abstract

“…1981). Similarly, various regimens of administration of agonists in secondary amenorrhoea have also not been encouraging (Jaramillo-Jaramillo et Cortes-Prieto et al 1979;Katzorke et al 1980). A novel approach to the management of infertility associated with abnormal hormonal profiles has been undertaken by Fleming et al (1982). The production of a hypogonadotrophichypogonadal state in these women allowed a Initiation of buserelin I predictable baseline upon which exogenous gonadotrophin therapy could be given.…”

Section: Ovulation Inductionmentioning

confidence: 99%

Clinical aspects of LHRH analogues in gynaecology: a review

McLachlan

¹

,

Healy

²

,

Burger

³

1986

BJOG

View full text Add to dashboard Cite

LHRH agonists are synthetic peptide analogues of hypothalamic luteinizing hormone releasing hormone (LHRH) with superior potency and longer duration of gonadotrophin release. Paradoxically, repeated administration causes pituitary desensitization with diminished gonadotrophin and oestradiol secretion. A state of hypogonadotrophic hypogonadism is reversibly induced; plasma oestrogen can be reduced to castrate levels. LHRH agonists reliably induce anovulation but are unlikely to replace existing contraceptive methods in most normal women. By contrast these agents offer, for the first time, the prospect of inducing a reversible pseudomenopause essentially free of side-effects. LHRH analogues promise to have a profound impact upon the management of a diverse range of oestrogen-dependent gynaecological diseases both benign and malignant. In particular, they may shortly become the gynaecological treatment of choice in endometriosis, as well as becoming part of the management of common gynaecological disorders such as dysfunctional uterine bleeding and uterine fibroids. R.

show abstract

Clinical Evaluation of the Effects of a New Long-Acting Superactive Luteinizing Hormone-Releasing Hormone (LH-RH) Analog, d-Ser(TBU)6-des-Gly-10-Ethylamide-LH-RH, in Women with Secondary Amenorrhea

Cited by 16 publications

References 14 publications

Clinical aspects of LHRH analogues in gynaecology: a review

Clinical aspects of LHRH analogues in gynaecology: a review

The effect of D-Trp6-LRH upon secretion of gonadotrophin – a possible therapeutic application in anorexia nervosa

Clinical aspects of LHRH analogues in gynaecology: a review

Contact Info

Product

Resources

About